[1] Bauer J, Andersen AB, Askgaard D, et al. Typing of clinical Mycobacterium avium complex strains cultured during a 2-year period in Denmark by using IS1245. J Clin Microbiol, 1999; 37, 600-5. http://jcm.asm.org/content/37/3/600.short?related-urls=yes&legid=jcm;37/3/600&cited-by=yes&legid=jcm;37/3/600
[2] Dvorska L, Bartos M, Ostadal O, et al. IS1311 and IS1245 restriction fragment length polymorphism analyses, serotypes, and drug susceptibilities of Mycobacterium avium complex isolates obtained from a human immunodeficiency virus-negative patient. J Clin Microbiol, 2002; 40, 3712-9. doi:  10.1128/JCM.40.10.3712-3719.2002
[3] De Groote MA, Pace NR, Fulton K, et al. Relationships between Mycobacterium isolates from patients with pulmonary mycobacterial infection and potting soils. Appl Environ Microbiol, 2006; 72, 7602-6. doi:  10.1128/AEM.00930-06
[4] Daley CL, Griffith DE. Pulmonary non-tuberculous mycobacterial infections. Int J Tuberc Lung Dis, 2010; 14, 665-71. https://www.ncbi.nlm.nih.gov/pubmed/20487602
[5] Simons S, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis, 2011; 17, 343-9. doi:  10.3201/eid170310060
[6] Kim SY, Lee ST, Jeong BH, et al. Genotyping of Mycobacterium intracellulare isolates and clinical characteristics of lung disease. Int J Tuberc Lung Dis, 2013; 17, 669-75. doi:  10.5588/ijtld.12.0575
[7] Xu HB, Jiang RH, Li L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis, 2014; 33, 347-58. doi:  10.1007/s10096-013-1962-1
[8] Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet, 2014; 383, 2057-64. doi:  10.1016/S0140-6736(13)62639-2
[9] Maekura R, Okuda Y, Hirotani A, et al. Clinical and prognostic importance of serotyping Mycobacterium avium-Mycobacterium intracellulare complex isolates in human immunodeficiency virus-negative patients. J Clin Microbiol, 2005; 43, 3150-8. doi:  10.1128/JCM.43.7.3150-3158.2005
[10] Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med, 2002; 23, 553-67. doi:  10.1016/S0272-5231(02)00019-9
[11] Han XY, Tarrand JJ, Infante R, et al. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol, 2005; 43, 4407-12. doi:  10.1128/JCM.43.9.4407-4412.2005
[12] Koh WJ, Jeong BH, Jeon K, et al. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease. Chest, 2012; 142, 1482-8. doi:  10.1378/chest.12-0494
[13] Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest, 2008; 133, 243-51. doi:  10.1378/chest.07-0358
[14] Wei G, Huang M, Wang G, et al. Antimicrobial susceptibility testing and genotyping of Mycobacterium avium isolates of two tertiary tuberculosis designated hospital, China. Infect Genet Evol, 2015; 36, 141-6. doi:  10.1016/j.meegid.2015.09.015
[15] Ichikawa K, Yagi T, Inagaki T, et al. Molecular typing of Mycobacterium intracellulare using multilocus variable-number of tandem-repeat analysis: identification of loci and analysis of clinical isolates. Microbiology, 2010; 156, 496-504. doi:  10.1099/mic.0.030684-0
[16] Inagaki T, Nishimori K, Yagi T, et al. Comparison of a variable-number tandem-repeat (VNTR) method for typing Mycobacterium avium with mycobacterial interspersed repetitive-unit-VNTR and IS1245 restriction fragment length polymorphism typing. J Clin Microbiol, 2009; 47, 2156-64. doi:  10.1128/JCM.02373-08
[17] Pang Y, Zhou Y, Zhao B, et al. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PLoS One, 2012; 7, e32976. doi:  10.1371/journal.pone.0032976
[18] Adekambi T, Drancourt M. Dissection of phylogenetic relationships among 19 rapidly growing Mycobacterium species by 16S rRNA, hsp65, sodA, recA and rpoB gene sequencing. Int J Syst Evo Micr, 2004; 54, 2095-105. doi:  10.1099/ijs.0.63094-0
[19] Park H, Jang H, Kim C, et al. Detection and identification of mycobacteria by amplification of the internal transcribed spacer regions with genus-and species-specific PCR primers. J Clin Microbiol, 2000; 38, 4080-5. https://www.cabdirect.org/cabdirect/abstract/20013105463
[20] Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, et al. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS Res Hum Retroviruses, 2006; 22, 52-6. doi:  10.1089/aid.2006.22.52
[21] Kobashi Y, Yoshida K, Miyashita N, et al. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother, 2006; 12, 195-202. doi:  10.1007/s10156-006-0457-8
[22] Brown-Elliott BA, Iakhiaeva E, Griffith DE, et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol, 2013; 51, 3389-94. doi:  10.1128/JCM.01612-13
[23] Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Ch, 1988; 32, 1131-6. doi:  10.1128/AAC.32.8.1131
[24] Zhang Z. Drug susceptibility testing and molecular mechanism of resistance to clarithromycin in Mycobacterium abscessus complex. Medical school of Chinese People's Liberation Army, 2015. (In Chinese)
[25] Selander RK, Caugant DA, Ochman H, et al. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. Appl Environ Microbiol, 1986; 51, 873-84. http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.327.4297
[26] Hunter PR, Gaston MA. Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. J Clin Microbiol, 1988; 26, 2465-6. https://www.researchgate.net/profile/Paul_Hunter/publication/239530556_Numerical_IndexoftheDiscriminatory_Ability_ofTypingSystems_an_Application_ofSimpson's_IndexofDiversity/links/0f31752f5684a5f83c000000.pdf?disableCoverPage=true
[27] Dailloux M, Abalain ML, Laurain C, et al. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J, 2006; 28, 1211-5. doi:  10.1183/09031936.00063806
[28] Alvarez-Uria G. Lung disease caused by nontuberculous mycobacteria. Curr Opin Pulm Med, 2010; 16, 251-6. http://www.researchgate.net/profile/Gerardo_Alvarez-Uria/publication/41429018_Lung_disease_caused_by_nontuberculous_mycobacteria/links/0deec527b284a11924000000.pdf?disableCoverPage=true
[29] Satta G, McHugh TD, Mountford J, et al. Managing pulmonary nontuberculous mycobacterial infection. time for a patient-centered approach. Ann Am Thorac Soc, 2014; 11, 117-21. doi:  10.1513/AnnalsATS.201308-278OT
[30] Xu K, Bi S, Ji Z, et al. Distinguishing nontuberculous mycobacteria from multidrug-resistant Mycobacterium tuberculosis, China. Emerg Infect Dis, 2014; 20, 1060-2. doi:  10.3201/eid2006.130700
[31] Wu J, Zhang Y, Li J, et al. Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study. PLoS One, 2014; 9, e109736. doi:  10.1371/journal.pone.0109736
[32] Zheng C, Fanta CH. Non-tuberculous mycobacterial pulmonary infection in the immunocompetent host. QJM, 2013; 106, 307-15. doi:  10.1093/qjmed/hct022
[33] Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev, 2012; 25, 545-82. doi:  10.1128/CMR.05030-11
[34] Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis, 2000; 30, 288-92. doi:  10.1086/313644
[35] Kohno Y, Ohno H, Miyazaki Y, et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob Agents Ch, 2007; 51, 4071-6. doi:  10.1128/AAC.00410-07
[36] Heifets L, Lindholm-Levy P. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Ch, 1989; 33, 1298-301. doi:  10.1128/AAC.33.8.1298
[37] McGrath EE, Anderson PB. The therapeutic approach to non-tuberculous mycobacterial infection of the lung. Pulm Pharmacol Ther, 2010; 23, 389-96. doi:  10.1016/j.pupt.2010.06.002
[38] Zhang Z, Pang Y, Wang Y, et al. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. Int J Antimicrob Agents, 2015; 45, 491-5. doi:  10.1016/j.ijantimicag.2015.01.012
[39] Guthertz LS, Damsker B, Bottone EJ, et al. Mycobacterium avium and Mycobacterium intracellulare infections in patients with and without AIDS. J Infect Dis, 1989; 160, 1037-41. doi:  10.1093/infdis/160.6.1037
[40] van Ingen J, Boeree MJ, Dekhuijzen PN, et al. Environmental sources of rapid growing nontuberculous mycobacteria causing disease in humans. Clin Microbiol Infect, 2009; 15, 888-93. doi:  10.1111/j.1469-0691.2009.03013.x